1. Home
  2. CCID vs SCLXW Comparison

CCID vs SCLXW Comparison

Compare CCID & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carlyle Credit Income Fund 7.375% Series D Term Preferred Shares due 2028

CCID

Carlyle Credit Income Fund 7.375% Series D Term Preferred Shares due 2028

N/A

Current Price

$25.25

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Logo Scilex Holding Company

SCLXW

Scilex Holding Company

HOLD

Current Price

$0.21

Market Cap

0.0

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCID
SCLXW
Founded
N/A
N/A
Country
United States
Employees
N/A
31
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CCID
SCLXW
Price
$25.25
$0.21
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
N/A
4.0K
Earning Date
N/A
03-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$55,152,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.02
52 Week Low
N/A
$0.18
52 Week High
N/A
$0.18

Technical Indicators

Market Signals
Indicator
CCID
SCLXW
Relative Strength Index (RSI) N/A 47.61
Support Level N/A $0.20
Resistance Level N/A $0.23
Average True Range (ATR) 0.00 0.04
MACD 0.00 -0.00
Stochastic Oscillator 0.00 57.28

Price Performance

Historical Comparison
CCID
SCLXW

About CCID Carlyle Credit Income Fund 7.375% Series D Term Preferred Shares due 2028

Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: